May Measurement Month 2018: an analysis of blood pressure screening results from Botswana

Masupe, Tiny; Tlhakanelo, John Thato; Tiro, Mary Banyana; Motlhatlhedi, Keneilwe; Mamela, Abraham; Makwati, Obuile; Kololo, Masego; Phuswane, Orapeleng; Lesetedi, Onalethata; Motlhagodi, Amogelang; Beaney, Thomas; Ster, Anca Chis; Poulter, Neil; Xia, Xin; Mosepele, Mosepele

doi:10.1093/eurheartj/suaa021

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparatively, a slightly higher proportion (47.1%) of those with hypertension were aware that they had hypertension in MMM18 7 than in the current campaign (44.8%). Additionally, there was 6.3% absolute increase in the proportion of those taking antihypertensive medications and 7.4% decline in those on medications having controlled BP in MMM19 compared with MMM18 further underscoring the need for regular BP awareness campaigns and improved BP control strategies in Botswana.…”

Section: Discussionmentioning

confidence: 74%

“…4 , 5 Additionally, deaths associated with stroke increased from 2.1% to 2.5% between 2013 and 2014, respectively. 6 The May Measurement Month (MMM) campaign of 2018 7 also demonstrated a high prevalence of hypertension in Botswana (32.8%) but less than a 5th of these (19.1%) were well controlled. Furthermore, there were high levels of unawareness of hypertension (52.9%) among those with hypertension and only 54.4% of those on treatment were optimally controlled.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

May Measurement Month 2019: an analysis of blood pressure screening results from Botswana

Tlhakanelo

Makwati

Beaney

et al. 2021

European Heart Journal Supplements

Self Cite

View full text Add to dashboard Cite

The May Measurement Month (MMM) 2019 campaign aimed to raise awareness of the health issues surrounding raised blood pressure (BP) among the general public. It also sought to identify and facilitate reduction of BPs of participants who require intervention to lower their BP according to current country treatment guidelines. Participants aged ≥18 years were recruited on site through interactions with the study team, educational fliers, and as voluntary walk-ins in response to the media engagement prior to the campaign. Blood pressures were measured using validated upper-arm cuff electronic devices provided by Omron Healthcare in partnership with International Society of Hypertension. With the participant seated, their back supported and legs resting uncrossed on the ground, three BP and heart rate readings were taken and recorded, 1 min apart. Participants’ basic demographic data were also collected. Hypertension was defined as being on treatment for hypertension, or a systolic BP ≥140 mmHg and/or a diastolic BP ≥90 mmHg (based on the mean of the last two of three readings). Of the 5459 screened participants, 1750 (32.1%) had hypertension, of whom 784 (44.8%) were aware they were hypertensive and 726 (41.5%) were on antihypertensive medication. Among those on antihypertensive treatment, 47.0% had their BP controlled (<140/90 mmHg). Only 19.5% of all those with hypertension had their BP controlled. A total of 1024 (21.6%) of the 4733 participants not on antihypertensive treatment were hypertensive. Intensified preventive and treatment measures to control BP at the health system, individual and population levels remain a critical requirement for Botswana.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Introductionmentioning

confidence: 99%

May Measurement Month 2019: an analysis of blood pressure screening results from Botswana

Tlhakanelo

Makwati

Beaney

et al. 2021

European Heart Journal Supplements

Self Cite

View full text Add to dashboard Cite

show abstract

Prevalence and control of hypertension in a high HIV-prevalence setting, insights from a population based study in Botswana

Mosepele,

Bennett,

Gaolathe

et al. 2023

Sci Rep

View full text Add to dashboard Cite

In a population-based representative sample of adults residing in 22 communities in Botswana, a southern African country with high HIV prevalence, 1 in 4 individuals had high blood pressure. High blood pressure was less prevalent in adults with HIV than without HIV. Sixty percent of persons with high blood pressure had not previously been diagnosed. Among individuals with a prior diagnosis of high blood pressure who reported being prescribed anti-hypertension medications, almost half had elevated blood pressure, irrespective of HIV-status. One-third of adults in this setting (mainly men) declined free non-invasive blood pressure assessments in their households. In conclusion, our study highlights alarmingly high hypertension rates in the community, with low levels of awareness and control, emphasizing the urgent need for community level BP screening and active management to reach recommended targets.

show abstract

Designing an implementation science clinical trial to integrate hypertension and cardiovascular diseases care into existing HIV services package in Botswana (InterCARE)

Youssouf,

Mogaetsho,

Moshomo

et al. 2024

Trials

View full text Add to dashboard Cite

Background Despite success in HIV treatment, diagnosis and management of hypertension (HTN) and cardiovascular disease (CVD) remains suboptimal among people living with HIV (PLWH) in Botswana, with an overall HTN control of only 19% compared to 98% HIV viral suppressed. These gaps persist despite CVD primary care national guidelines and availability of free healthcare including antihypertensive medications. Our study aims to develop and test strategies to close the HTN care gap in PLWH, through integration into HIV care, leveraging the successful national HIV care and treatment program and strategies. Methods The InterCARE trial is a cluster randomized controlled hybrid type 2 effectiveness-implementation trial at 14 sites designed to enroll 4652 adults living with HIV and HTN plus up to 2326 treatment partners. Primary outcomes included effectiveness (HTN control) and implementation outcomes using the Reach Effectiveness Adoption Implementation and Maintenance framework, with explanatory mixed methods used to understand variability in outcomes. InterCARE trial’s main strategies include healthcare worker HTN and CVD care training plus long-term practice facilitation, electronic health record (EHR) documentation of key indicators and use of reminders, and use of treatment partners to provide social support to people living with HIV and HTN. InterCARE started with formative research to identify contextual factors influencing care gaps using the Consolidated Framework for Implementation Research. Results were used to adapt initial and develop additional implementation strategies to address barriers and leverage facilitators. The package was pilot tested in two clinics, with findings used to further adapt or add strategies for the clinical trial. Discussion If successful, the InterCARE model can be scaled up to HIV clinics nationwide to improve diagnosis, management, and support in Botswana. The trial will provide insights for scale-up of HTN integration into HIV care in the region. Trial registration ClinicalTrials.gov reference NCT05414526. Registered 18 May 2022, https://clinicaltrials.gov/study/NCT05414526?term=NCT05414526.&rank=1.

show abstract

May Measurement Month 2018: an analysis of blood pressure screening results from Botswana

Cited by 3 publications

References 3 publications

May Measurement Month 2019: an analysis of blood pressure screening results from Botswana

May Measurement Month 2019: an analysis of blood pressure screening results from Botswana

Prevalence and control of hypertension in a high HIV-prevalence setting, insights from a population based study in Botswana

Designing an implementation science clinical trial to integrate hypertension and cardiovascular diseases care into existing HIV services package in Botswana (InterCARE)

Contact Info

Product

Resources

About